<SEC-DOCUMENT>0001193125-12-218410.txt : 20120508
<SEC-HEADER>0001193125-12-218410.hdr.sgml : 20120508
<ACCEPTANCE-DATETIME>20120508160731
ACCESSION NUMBER:		0001193125-12-218410
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120508
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120508
DATE AS OF CHANGE:		20120508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		12821484

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d348576d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Current Report </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported):&nbsp;5/8/2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Dynavax Technologies Corporation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission
File Number:&nbsp;001-34207 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>33-0728374</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2929 Seventh Street, Suite 100 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Berkeley, CA 94710-2753 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices, including zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(510)
848-5100 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;8, 2012, we
issued a press release titled &#147;Dynavax Embarks on Transition to Commercialization.&#148; A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)
Exhibits </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 8, 2012, titled &#147;Dynavax Embarks on Transition to Commercialization.&#148;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signature(s) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL></B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;8, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael S. Ostrach</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice
President</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated May 8, 2012, titled &#147;Dynavax Embarks on Transition to Commercialization.&#148;</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d348576dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g348576g19e26.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Ostrach</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President and Chief Business Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">510-665-7257</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>mostrach@dynavax.com</U></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX EMBARKS ON TRANSITION TO COMMERCIALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BERKELEY, CA &#150; May 8, 2012 &#150; Dynavax Technologies Corporation (NASDAQ: DVAX) announced today, that following the recent submission of the U.S.
Biologics License Application (BLA) to the Food and Drug Administration (FDA), it intends to begin developing a commercial operation capable of independently launching HEPLISAVTM in the U.S. The Company believes that being able to bring HEPLISAV to
the market successfully will ultimately help maximize long-term value for its shareholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the goal of laying the foundation for
long-term success, Dynavax plans to strengthen its senior team with the addition of experienced commercial leadership. Subsequent to a recommendation from Dino Dina, the Company&#146;s Chief Executive Officer, the Company&#146;s Board of Directors
has agreed to initiate a process that they anticipate will include his succession. Dr. Dina plans to continue in his role as CEO through this process and will support the transition to his eventual successor. He will also continue as a member of the
Company&#146;s Board thereafter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Dina joined Dynavax in May 1997 and has led the transformation of the Company from its early days
through the research and development phase. Said Dr. Dina, &#147;I believe now is the right time to prepare Dynavax to effectively capitalize on the significant market opportunity we have ahead of us when we are able to bring the benefits of
HEPLISAV to the public. I am committed to working with our Board to plan for the success of Dynavax.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Dino&#146;s leadership and
vision have been critical in making Dynavax what it is today, a diversified company with an important product candidate in HEPLISAV and a maturing pipeline. We fully endorse the strategic direction for Dynavax that Dino has set and appreciate
Dino&#146;s commitment to a smooth and seamless transition process,&#148; said Arnold Oronsky, Ph.D., Chairman of the Board. &#147;We are confident that Dino and the leadership team will remain focused on Dynavax&#146;s success and building value
for shareholders in the years ahead.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About HEPLISAV </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">HEPLISAV is an investigational adult hepatitis B vaccine for which a U.S. BLA has been submitted to the FDA and a European Marketing Authorization Application (MAA) is expected to be submitted in the
third quarter of 2012. HEPLISAV may not be marketed in the U.S. unless and until a BLA is approved and may not be marketed in Europe unless and until a MAA is approved. In Phase 3 trials, HEPLISAV demonstrated higher and earlier protection with
fewer doses than currently licensed vaccines. Dynavax has worldwide commercial rights to HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Dynavax </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company&#146;s lead
product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide higher and earlier protection with fewer doses than currently licensed vaccines. A U.S. BLA for HEPLISAV has been submitted to the FDA and a
European Marketing Authorization Application is expected to be submitted in the third quarter of 2012. For more information visit www.dynavax.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains &#147;forward-looking
statements,&#148; including those relating to the potential approval of HEPLISAV, our plans to transition to a commercial operation, our expected capabilities, our beliefs with respect to strengthening our senior leadership team and helping maximize
long-term shareholder value, our expectations with respect to laying the foundation for long-term success, our plans to initiate a process that includes CEO succession, the identification and successful procurement of a successor CEO, and
Dr.&nbsp;Dina&#146;s continued role as CEO and Board member of Dynavax and support of the transition, that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the
risks and uncertainties relating to the efficacy of our CEO search and hiring process, Dr.&nbsp;Dina&#146;s future actions, the successful integration of and execution by any future CEO, as well as risks and uncertainties inherent in our business,
including whether successful clinical and regulatory development and approval of HEPLISAV and our process for its manufacture can occur in a timely manner or without significant additional studies or difficulties or delays; whether our studies can
support registration for commercialization of HEPLISAV; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process, including whether the BLA will
be accepted for filing and if it is accepted, approved; our ability to obtain additional financing to support the development and commercialization of HEPLISAV and our other operations; our ability to successfully transition to a commercial
operation and execute on our commercial strategy; possible claims against us based on the patent rights of others; and other risks detailed in the &#147;Risk Factors&#148; section of our current periodic reports with the SEC, including in our
Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2012. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on
Dynavax&#146;s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"># # #
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g348576g19e26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g348576g19e26.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`6P#1`P$1``(1`0,1`?_$`,4````&`P$!````````
M```````&!P@)"@,$!0$"`0`!!0$!`0```````````````0(#!`4&!P@0```'
M``$"!`$(!@4'"`L!``$"`P0%!@<(`!$2$Q0)(3$T%367UQA802(R,Q874F(C
M4V-APT1D-M89T9(E=9:V)SA1@B14=$5EE=4F5@H1``(!`P,"`@@$!`0$!@,`
M``$"`Q$$!0`2!B$Q01-1(C+3%%46!V%Q0I.!P2,S\)$D%;%2@D.AT9+2E!=B
M4T7_V@`,`P$``A$#$0`_`++G/C"=\JV:[=OYN8FJ_0D*^0FJ[DD"U&K5>,A)
MBT1D.U@#R$+.-W+LT:RE>X.3H^8J=/\`7`0-\)48$A:#569'"E]QIZ-1?<!L
M,A^7^V6&D:W=-&4A(2AR%R`\-:%4Y)_(M9V!B$F[E_+H3`IM10EU#&%,A51,
M4``P!W[R.VP5&J\*"5J,32FI;;1[1^<,H\[K%=KVS,;:V*HM'2#JUC/1!WA2
M^)#UK1FW@91),RI"@=1!V4Q2AW`IA#L,?FGQ`U9-LOZ"0=,>K_-KF#P6V-SC
M_)AT]UNJQBC=5TG+."/IU[67JABL;=G]U71:OI9JLF@;PM9,50!1-1N?TRQ3
M&*[8KBJ]-0B66%MLG4?X[:L(TK4Z%H&<1&M5BR1SO/YJ`/9F]C7739,6L0W1
M56D%Y11T9(L8>(%NJ1X582"U414*IX1(;M"00:'OJZ&5EW#V=%B+Y'<?)LI3
M1&YY!(@;XE])I%/6$P=A'N4I)@3&#L41[@'R=&UO0=)YB'L1_GH^UJ]TBZ'D
M$Z=<JK;%(D6Q94E:L,1.GC#/2JG9ED"Q;QT+(79$#BD"GA\P"&$O?L/10COI
MP8'L0=<6Q:[E%0G"5BV:90*O8U&B#].!L5QKT),*,G1UDVSLD=)R#9V=LX4;
MJ%(<""4QB&`![@/10GKX:0LH-"177JVN92A6%+LMIN?ITU&2"'6MI[E70K24
MN8Y4PBU)WZ1^BR2(J'*7R!5!7N(!X>X]%#6GCHW+2M137"B^0F"SDK%P<+M6
M42\U-O"QT/$QF@U1](RC\XB";)@R:RJKAVZ5,'8B9"F,<?@`"/1M;T'0'0]`
M17\]+!TFG:)EQT?/<[18.+_>J?2$)15=&,5MMEAJXG(K-4RK.4F!I=XS!XHW
M2.4QRI^(2`8!'MW#I0">VD+*O<@:*=3Y`X7?+$WJ-)V'-+=:';9R]:UZMW6O
M34PX:,D_.=N48^.D'#E1%JE^LH8"B!"_$>W1M(%2.FD#H30$$Z5_I-.TG5BU
MW,:C=:CG%FO-<@[W?0<#3:K(R*+>9L8-A,588QH<?&OV.0Q2_)XS`)2]Q`0Z
M6AI7PTTLH(4GUCH\24BPAXY_+RKQM'1<6R=2,E(/%B-V;%@Q04<O'CIPJ)4T
M&S5ND8YSF$"E*41'X!TFG$T%3VTB,?RIXRRJ`.8_D'C#I`R8*@JGI=/\(ICW
M['#Q2Y1$![=.VMZ#I@DC/9A_GHT47<<:T^8DZ_G&IT&]S<*R2DI:+J-KA;`]
MCF"RX-D7CQ"+>.3H-E'`@0#F[%$WP^7I"I'<:571C12"=%/\5W&0KJ08J<@,
M=0>Q3YW&2;)SHE5:NV$BP<*M'K)XV<2:2[=TU<H'34(8H&*<H@(=PZ7:WH.D
M\R.M-PK^>E-HNB4/3X,UFSJX5R\5TK]W%C.5:793<4,C'F(1ZR*_8++MCN&A
MU`!0H&$2B/8>D(([Z<&#"JFHUS+1KN8TJW4V@VR\UROW/0EUFU)K4G(HMI:R
MKH*)I*)1;4X^-<WG+%(7Y/&<?"7N;X=%"17PTA900I/4Z47I-.T6;==*A0(1
M>RWFT5^GUUJLV;N9VS2["#B&Z[U<C9FBM(R2[9HFJZ<*%33*)P$YS``=Q'H`
M)Z#2$A15C0:([/D'@L@T]>RVS)7+(``1=(Z+4#H%`1$H"=0)CPD[B`_+VZ6A
M]!TF]/2/\]=<FQ9*I437\FGY^:B$D#Q)KH%PK_\`"@2B;KT1X[^(1D/HD7I7
M@>5Y7F^/S/U>W?X=%#6E.NC<M-U131>-R/X]%;^J-NN/>G\PB(*AI5-$HK*'
M*FFD7M,B)E#G.``4.XB(]&UO0=)YB?\`,/\`/2R^8G_>$_YQ?^7I-/TQSW*O
M_)#O?_4=9_[^57I\?MC4-Q_9;4.'LR'.7E#=2%+W(IBL_P"8;L(^'P7"E&)\
M0^`>(1_3U++[/\=5;7^X?RU9UZKZT-0E^]9GD:]R[)=43:($FZY>EZ0Y?E3*
M#E>$M4))2R3-94`\2B+64KA5$RB/8AE5!#MXS=Y8CU(U4NU]4-Z#HJ>RQI#J
M9K.V8E-'^D86%<PMT@X]X!'+1!E:4Y"&M$>#=8#D%DZ=QK=8R?;RS*+JB(=S
MCW64=CI+5J@H=)1[KW"6$H:S7D9D]48Q%/E%F\-J5>@8YLRBZ],N#D;0EP91
M[-)-!A'S:IP:/O+(5,CSR5/VEU!!8WKZI[Z;<Q!?77MXZ?G[5^O9+HV'JP-2
MI%'SW3:26)A]/C*E`1-?5M@MFRC>OWUP2/;-UI%.;;E5!8R@J>G?E7('A(<G
MB9("#U[:FMW5DH``P[_^>L_)G-Z)S#Y!U+`&M3K<G#98I#7OD=IB4*Q/9(B)
M`KAQ1<1B+81$LFQD;LHNL^D44E@%K&)@<.QU0`1256OI[:)%$K[/`=S_`"T^
MZ-Q3'XBBES".RZ@-<Z`P*&I!:E!GJZJ_<AA=N(51D=@Z>F.F4QEU"&6,<H&$
MPB'?IE36OCJ;8NW;0;?1JL9S5XFKU[DOO3'CW1Q1J685//\`3)RKUHRGKZS&
MVID8)"5K46D)GAXF*EV1G"J;41,Q36`R9`2(/@L*WJC=XZH31_U&V#H*'4A?
MMT>Y"G?BP>#;_.I)WD"-XS/M&DETTV]Z(4`3:5VR.SF*DE<2D`I&SDP@65`/
M"80=?.(W2G5>VIH)]WJ.>O@?3J7/2LJSK6H!6OZ-1JG>8\J+P&36U0,=-D8.
M':'DJ.8\[U!5:.='*!0%5`R:O8`[&^`=1@D=M6656%&`.F#^U3FU&@N+]6N#
M.FUIG?)&QZ-&S]L2B68V9^$3=YR%1:.IHZ9Y'TS9C'))%1!0J0%(`^'N(B+Y
M"=U/#4-NJB.M.M3J3OJ/5C51[G+LE\OO)^2Y!UGU[&FTZ_.,YQBW('$T6XE,
M3>QSV46C7!3#XC+6*6%\8.P`HBZ*4/%X#=K*`!=OCK-F9C)O'8&@_AJT'B6H
MU_?<9HFGQ:""L/?ZJU?O8Q8A'"+1ZLD=C88)VFJ!R+?1LJBX:*%,`@?RQ[AV
M'JN05--:",'0-X$:@B]W;BC5\[D*3NV;5.'K-:LBQJ5>XFN1#.)AV=E327?U
MNP%9,$D6C9:<8I.&JYB)D*95JB(]SJ"(S1-7H=4[F,*0ZB@[:DU]LZQYO<^*
MV?3E,J54K-D@6!J!H`U^#CHMZ[LU7%--=]*.FJ)';]:>8K-I,3K'.)CNQ_2`
M]1R5#==6("IC!`Z]M(ER<QC-^1/.+`L72I-3&-H-8L.W[G*Q\&P;R<S!N))A
M&52FV)^R10<N6E@F6@F526.)C-USG+V_2Y250G3)$628)0=!4ZE:K]<K]3B&
M<!5H.(K<%')`BPAH*-9Q,6R2#Y$VK!@B@U0)_D*4.X]1=^^K``'0=M51O<!U
MV\:-R9F-KK0R#2BYS>#Y)D]R:F\49_%&2JL)^=4CG:8AXG0628,\`>W8Z!B`
M`F\!NUE``M/$ZSIF+2;Q[(-!_#5FKCOL,5OF*YUK,1X"$N%<:/))F00'Z+L+
M43Q]DB3``B(#&3K1PB'?L)BD`W;L(=5V%#35]&#H&'CI3+'6*W<8=U7K;7X2
MT0+[RP>PEABF,U$N_)4*LCZF.D4'+184EB%.43$'PF`!#L(!TE:=M.(!%#U&
MJPON8\*V''*^QFNYC`,F>17J52)]$(QJ3B)H-X1+ZL80S54BC7^&;&FV.X9H
MG#RBG(NV\()@D4;$;[A0]]4)XO+;<OLG_P`-214WF3QHM/!LUOE,LSY[(0KR
M,I2_'%C4J^YCIK:GYRC6XNN4\K`S16.M$F8)!LY(W%1%L"W<3+H'`6%&W_SU
M.)8S#4@5]'XZ._"_V^,]S"IAH&V9S0K-MMXD%+=+Q[RM1$A6\P^D5U)!G3*9
M$N$'47&A""Y\*RZ!.XJ@":9O)13$4=R30=M+%`JC<X&\_P#AJ3OP$_HE_P":
M'_)U'JQIC?N5?^2'>_\`J.L_]_*KT^/VQJ&X_LMJ'+V8A4#D_>`*4!(.*SGF
MF$>PE[7&E^7X0_3XC?+U++[/\=5K6OF'T4U9SZKZOZAD]ZJX,F&'971143&2
MM.H_Q`DCXB^<$=4:U,(.W`$_:!(KRRMB"/R=S@'4L0ZD_AJK=FB`>DZ23V2:
M#(E/NVI+MU$HER%4H$4Y.F8$WCYB,A8)PB*@AX#^A3?,0/V'X&5[?H'I93V&
MFVB^TW\-3JVVJ5Z]5>?IELBVLW6K1$/H.<B7J8*-GT9)-SMG2"@#\2B9)0?"
M8O8Q#`!BB!@`0A!H:C5L@$4/;53"YFT[VTN7%NC<UL#61<0\6X0A%Y9)1U'V
M6A72/%W"M;0P14;^?(0SHJ2A^PE*+Y@50O\`9G\(V>DB]=9IW02D+_@:LZ<;
M<9AL3R^*@&CYU8;-855;GHMXE?UYZ^WZR%(_L-GF5S"90RCERIY3=(1$K9HD
MDB7X$[C`QJ?PUH1J$6GCX_B=+YTW3]1RYR[(?W.^2#,J?[/&W(_..(`'<Z,V
MNH4"@'?QE,E(``B/80$O;Y.I#_;'YZ@4_P"H8?\`XC3'O<6]MP6QIOD#QR@!
M(F4R\UHV7P3?RS-SD'U+NYT-BT*4R9B&**S^-1`!`P"NV#OXTA<DG@VHIX/U
MQ_Q&CC[<WN1%M@0&!<@ITH6H0;1.<Z5)K@"=K``*BRJ]L=J"!4[.``!&CTX@
M61^":H@Y\)G`\?ZE[:()Z^H_?P.G?^V64S;CG.Q)C*&&"WC=8?NH`?Z+H4JI
M^I\"F$O]OW'N`#XN_P`.FR>U_#4MO['\3I7.;>T+83QKT:XQ9CC;)./3I%#;
M("H+MS=;HI]!0@LB(@*RSJ/,Z.\`A`$QBMA[!TU!5J:?*^R,D=]0FZ@DQE>"
M%*X\L.*G*F%N^7DCKL2]S>1K-JZ:Y"JZ>:'*RLHD^5D"0DLQE7X%4,AXRD(W
M%0H`G\)A[>ZHH=5&ZPA`K5'C3_/2]^RWN97,=H_'F7?^)2/5#2Z*BH<HE&-?
M';1=Q8-3&-W$C:2,R=E3+\.[M8_](>FRCLVGVK]T/YC4N7);%XWD'ANBY-(>
M6FK:(%<L&]4`O_1=HCCDDZS)@8Q3"0K.;9H&4[?$R7C+\AAZB4[375F1`Z%3
MJO[[5>Y/<(Y"6W#]$7/78702RD1(M)54K5M6M,H1)!3Q/#+]BM0>QK-\R6-W
M*!U4F_<>P!U/(-PJ-4K=]CE&Z`_\=2W<#HUS?R[7RWG$#%D^2.B/5Z:#@A1<
M1V.9\HXJ.?,R'$/,3+(),G#LX!V*H"B9_C\.HGZ47T#5F'UJRG]1_P#`:6SF
M-M/\@^.6EZ$T4*%C3AOX=I3?Q""SRZVE4D%7$VR90$ZZK1Z]!T9,H>(R3<_;
MI%&YJ:?*^R,MXZ@^NR:,AP)KO'!/BGRKC]!I2K70#7R3R-PC7E=#%\[D+E-2
M<D#Y63^AI**E'S8%!0!0J`(B8H>7V"8>WNJ*:J'^SY>UJCK6GCI8?9;W0I%=
M(X\3#_N58"Z;0D%5"^$>_IXJ[1[7Q#W,(B+!X5,O])P?M^T/391^K3K5^\9_
M,:G\ZAU=TAW)1CD,AA6FM]X49H9.%6?KV]V[/Y9V+1`"JM7L8H!3*ISS61*B
M>/%(#+"]!("`8P@456M>G?3)`I0[_9IJIWF$U:.&_(+)]1N.:R;J$3*SOM8A
M;S$-D)6P9M92O6$;:8U`%%V,9<6T.N9=N(&$S*0+X#@4![]63ZRD#6<I,3AB
M.G?^&KA='NM9T>GUN^4R5;S=6MD.RG(.4:F[I.F#Y$JR0F*/ZZ#A(1$BJ1P!
M1%4IB'`#%$`K$4-#WUI@AAN'8Z-72:74*/N$<OFU_P`^UOBWFN+[5:K6\EF]
M5G[0%!F$ZI&A6[+&RKYU"N&:3][8BNC1`I('(BD@('\SQB!0*:5%H0Q(IJI/
M)N4QJ#746?$2V;_Q0V1CJ##`=4M$8O#2-7M-=-0[E'KRE>E%V+M;Z/?FKZZ;
M239/HU!=$QR&3/X!3-V`XF+(VUA2HU7B+QONVFFII9CW6J$SB#'BN.7)Z0M1
MD""A6W^<&AVYGB@?J(+S7K9#RT!/\/,3:K&$/B"8C\.HA&?2-6S<+3V6K^6H
M\YKC]S1]R/9FNA:72WF)YVT;)Q4.]M<;(1L?5*D5RJZ.RJ]?E"LK!;;!(*F,
M=9VHBU:K+>'QJ(I)II%?5(Q0=3J`I+.VYA1=6#<5QRDX'FE8RO/V)V=<K#,R
M)%7!B*R,M(.5#.92<F')2)^KE99\J=98_8"@)@*0"IE(4L))8U.KJ($7:O;1
MON-O@*#5YNY6EVNQKU=8J2,L[:QLG,.$&B0E*8Z,7#,Y"5?*>(X`":"*BAA'
MX%Z0"O0:4D**GMJJIS[DY?D/R3G]/RG/=8GJ6I5:?%HRKC++W%"NM"MG"3Q=
M-K(02#HC,3J`":BA">/X]@[?$;*>JM#WUG3U>0LH-*#PU9:PC?<VW>!?.L\>
MV!<U6+$Q\^RLE-M=.?QSQZS.HW1,WL\1%@[$Q6JGB,V,L0@E[&,'<O>!@0>N
MKZ.KBJZ4F]WFLYK49V]7)\M&5BML_7S#]O&R<NLV:BLDW`Z<;#,Y"4=F%9<H
M>%%%0WQ[]NP"((!4T&G,P4;CVU#%4N6>45[W!-CVV3'0$,AN>*U"D0US+EFD
M*,'5B@74$]7!9@6L!+MV9$TW*95CMO`)TQ[#X3`(RE24`\:ZJB11,7Z[2/0=
M375FQP]PKL%:Z\Z.^@;+$1T[#/%&KQB=U%RK1)\Q<'92"#5^T,LV7*84UDDU
M2"/8Q0,`AU#VZ:M`@BH[:@Q]QGVX!7&>Y"\>(/P/""XG-)S.'0$@NSD,9V^N
M=)9MR]R2)3`*S^/3`/.["NW`%?&FI,C_`*6U4G@_6G\1IQGM'SB33AK-V&9>
MN5F['4=-EY1ZH#N1=BDW;1#^0<&32(Y?/')NQU#%(4ZRJ@CV`QS?%LOM?PT^
MV/\`2J?2=(AR#Y/5#<^1/&B0&@[K(<:<?L\EHMILB&*Z$=K8[^S9JDIWEP:\
M&G*.X.ONTTCJK&0`X^K4`J9@+W%RJ0I[;CIKR!W4T/E@U['OJ7N=UJB1.4&U
MR8/-#0G4#&S)O#4+.^G5XR>,T;,6YZ8WAU[0+QTI()IG:F9@LF)A\PI0*80B
M`)-/'5DLH7<>VJL&;*73CURT:;-DF5[5)9+6]$EG,45SF%RC)*4RN><N&4I#
M+-743X4G*$&_42;@J)?$NW2.8"C\`L&C+0TKK.6J2;U!VU]'AJT]CNQ4S<Z8
ME>J+_$)(920>12B%HK$[49AK(,`1,Z;N(BP,6#P"D*X()52%.BH`_J'-V'M7
M((-#K15@XJ.VJ_WN.<1IYWS.H2F?Q;Q"/Y0R42W%\R:KF9P]Z2?LX2XOEUD0
M$K9,8APUEE3',0#G.X']`]3(WJ]?#5*>,^:*?JU8DJ]=KN8T.!JT.B$?5J'5
MH^&8))(&.+:&KD6DU2'R&R9U5E0:M/$8"%,=0_?L`F'XP]S^.KP`44'8:ACY
M,<GJCO&W\:D6M`W*9XV97?'&CZ%96N,:$9E8K5#M%0IS5O!NH)"3D(6&>%\;
MI042F%-X8"$-X![RJI"GMN.JLD@=UZ'RP:GH=2\/=AH;3)_YRO5ITM"5@VDY
MYAJ=:U;`>/D5D6C5$U+)"GMGK5W#DB8MA9><43=S%`H"(14-:>.K.X;=WAJK
M#5C7+"^7)-NQ/*MGD<LK>G24U`D=9?=(E[(9S..ET)ZO*-G$0`H`6&DW+-OY
MOA$PI)*&*4?@%@]5HQ%=9PJDF]`=H/H\-67X+ECC<YC\EN0OK?#42&EP@)89
M[.[PPL;&9,I'(D8C5"P*\^[\:LL@4%FR"S8?&(^9V(<2P;37;XZOB12N_KM_
M+43^L\M*;R0Y$T6)U:H;!6N&V<R/\2I%6RN\.F^I:'%F1/!2%\C6<,O(,:-$
M+'541:>2NHJ*/B7(7S@!"0*57I3?JNT@D<;@?*'X'KIQ7NAM<)T/&8:&F_XD
M5UE.&&[8>ZJ>=W*SO')'`(I*PLBZA8)PRBH&TI)D053=K(*(*E2<`011["V.
MH/X:?<;"M#7=X:8[[>'*^\<6DI/+MVH.L,,=G%U)ZLSILYNK]2C3SDP#))^B
M1ACO7%8GP_MC@W(J9L\**A2""ZHE>ZANH[ZA@D,?JN#M_P"&IPOQ685__6RW
M_8#1O]T^HMIU<\Q?\`Z)ZW*Z51651#B?RY6!)51(%D<YIAT503.)/-2,.E%$
MR2G;N41`!$!^0.NQ7A\)`/\`O&%%1XSR^XUR)Y=,"1_M&8-#_P#IC]_K'^+*
M6_*7R]^S>E_>9TOT=#\YPO[\ON-)]7S?)\S^S%[_`$/Q92WY2^7OV;TO[S.C
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M/E&XCDA0C^'_`"S8H&4.J9%GE]%;)"JIV%144T-)(05#B'Q-V[C^GH^CH?G.
M%_?E]QH^KI1__'S/[,7O];?XLI;\I?+W[-Z7]YG1]'0_.<+^_+[C1]7S?)\S
M^S%[_0_%E+?E+Y>_9O2_O,Z/HZ'YSA?WY?<:/J^;Y/F?V8O?Z'XLI;\I?+W[
M-Z7]YG1]'0_.<+^_+[C1]7S?)\S^S%[_`$/Q92WY2^7OV;TO[S.CZ.A^<X7]
M^7W&CZOF^3YG]F+W^O/Q8RHB`CQ*Y>B(?(/\MJ5W#N'8>W_B9\.X='T=#\YP
MO[\ON-'U?-\GS/[,7O\`7OXLI;\I?+W[-Z7]YG1]'0_.<+^_+[C1]7S?)\S^
MS%[_`$/Q92WY2^7OV;TO[S.CZ.A^<X7]^7W&CZOF^3YG]F+W^A^+*6_*7R]^
MS>E_>9T?1T/SG"_OR^XT?5\WR?,_LQ>_T/Q92WY2^7OV;TO[S.CZ.A^<X7]^
M7W&CZOF^3YG]F+W^A^+*6_*7R]^S>E_>9T?1T/SG"_OR^XT?5\WR?,_LQ>_T
M/Q92WY2^7OV;TO[S.CZ.A^<X7]^7W&CZOF^3YG]F+W^A^+*6_*7R]^S>E_>9
MT?1T/SG"_OR^XT?5\WR?,_LQ>_UX/+.6`!'\)?+X>P=^P9O2^X_Y`_\`$SY>
MCZ.A^<X7]^7W&E^KIOE&9_9B]_HX?B&D/R\<CO\`L36/]^>J7TU%\SQ?[LGN
MM6_J.3Y;D_VD][J&S;_<6YPYIH7N#:544>/5CX\<!-0S2NVK,+)5K?%:;>*5
M>H:MO)-Y7="C[6>"86*&/,*J(E<QAT5O`!?"80`BGMN!^VG`<IC>.8N].2BY
M+R*TG>.=)(V@BEB9PH>$Q[RC;0#M<$>D=QY'FON#SC'9+.W]D,?)@<)<P(\+
MHZS2),0OJRA]H92:U*D4_2QHID4YQ\C=PQSBU7.67'>#@;96Z0\I&I;!0K1"
MNUIZQ\>)%NV?WD]5=MI1@->N=:A'I)`%%B.D2MV[CQ)&,4H#YKP'C&!S?+9>
M'<EDDANIQ+!;31L`B7BDB+S`5;?&[`I0;26*T(!)'?\`..29O#\5CY;QY$EM
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MBSN?O<3A,S%#!FKN[;S%$;`26CVTDT4L56(!#H4>A8`;:T8D!XONW<_=@X95
MO+X7CI!TBT:M94M#U.V1=X(9Q'1^$XO74Y;07K5!.;@U0GI)],L&\?X5%3J"
M1<J:*AP``XG[-_;K"\XNKN?DTEQ%B(C#!&T71FN[E]L(/JOZBA7+]`!526`U
MV7W:Y]F.&6]K!QV."3*2^;-()?86V@3=(3ZRT8LR[>Y(5P%)[.>Y/\A-,;<`
M+QRIXH)UR9N;7%(;=Z"QM42YL4+,58D9$WB;CW<?&2D0Z6>N*,+PJ`IKE$CL
M"?JF["4>3XIQO%-]QH.(\O\`-2R-^UI*8V",LFYHD(9E8`"7;6HZK7MWUTW)
M>0Y'Z`EY7Q4Q&Y^"2ZC\Q3(IBHLKU564D^3NI0^U3\M)MPTYKVGF1N.@.:.2
ML?APH7'KCM-KOF[%RXL3W>]LKRVES<$E/_2(L1BJ'1'+!H\9`U\Y*0==SJ_#
MP=:O.."6G",!;)?^;]3W&2O%`)`06EJ_D*Y3;7=+*'96W4*+T7QUE\+YO=<S
MSEPUCY?TY;XZT8G:=YNKE/.90^ZE(HB%=-M0YZMX!N&@>Y_H%2]TBH\8FT51
MS<6!NU3XX76WKD,>\(<D]`SN4T2L,XYR$VF1*MI`YBXMP!F!R%>**@*P'\)>
MNGQOVHQM[]I9N5L]Q]6^1)>Q1C^T;*&987+#;[?220>O4J%]6E3KGLA]S\A9
M_="+C(2`<6\^.TDD/]SXN6)I$"G=U7<8XR-E`0_K5H`Z7W,^46O\+,:J')JA
M-Z38,VSS2ZHTY`4*R(^GM=MS2VRS&NG'+IQ2:CFK"\1$J\2.DW6;O$W**JAS
M%*5`WBY'[5\3PO.LY-Q7(F>/)W-K(;25.L<<\:E_ZZ;23$R@U(*D$`"I84ZG
M[F<HR_"\-#R6P$$F.@N8UNHGZ.\4CJG]%MP`D4GH"""&W'HA!6C@WINN[;QF
MSC;-H7HQ;/L+%QI4)!9XGYD!3\_MK@TI0*DXE_I>8"Q6*'JZK<)1Z4R)3R!U
MDRHD!(.^'S[%8;`\JNL#@Q<?"63"!GF]N2:,;9I`NU=B-)7RUZ^H`:FNMK@V
M4RV<XS;9S,>0+F\7SE2+JL<3]8T+5.YPM-YZ48E:>K4K1LK#7I3-+2PP:Q4>
MIZTX;L0IUATB`EK12HUR268*2)YV!@Y2%E9!)>%(Y22!%RD)'!TSCXBE$HX>
M#DPL64BDY#%<38<$^8D#K'*PVG;L=U911MI-5-0".A-=;68CR\N-D3!20Q94
M[=C3*SQCUEW;E4@FJ;@*'HQ!((%#'E[4/(/EORMQN5WGD59L7?U2PS=FJE&K
M&9T6RU6>A)C/;Q9Z?9I"R24U:)]C*,9H8E%9DFW32.@43>88PCV+Z3]X.-\-
MXAG$X]QF*^6[BC225YY4D1EFB21`@5$*E=Q#$UKX:\\^U'(>6<KPASW(I+,V
MTCND:0QNC*T<C(Q8LS`@T!%/XZ:)PJ]P;E?RBY03>:3.M8O7(.L;_L%*=Y@W
MXM;D\FIW-LKFY))5TUWQI8U\A@K+(P[7]5)V85P62$!0$RJ9![/G?VWXAQ/B
M<>5@L[Z6>7'6\HG-_:A4GG44!M"@N'0,>I44H?:Z$ZY/A?W"Y/R?D\F+FNK2
M..*_FC\D6=SN:*$U)^)!,"N5!`JU:@&AJ`73\J>4_+"9YEP/!OAL.1U2\1O'
M29Y*WG0]DKT[:XYVP0LJU3JN>5F#B)^N)H.)R83)ZZ2656*V17`2$`R1P4Y+
MB/$>(0\'DY_S?XR;'MDUL8H;9TC8$H)))G9D>H5:[4`%2O6H84Z?E/*^4R\T
M3@W#_A8K]<:UY)+<*SA@',:1(`RT)?;N8UZ-TH5(93-RY,\D<B]LG0N3UQH%
M)SCD[0\6?VR=H@RK/0*!#7N+?$CG!&\A7Y]9"7KT@!?5(I$D3JH)+E255,HF
M<1R<#Q;C&9^Z=MQ2QN)[GBUQ?"-)=IAE:)EW"H=`5=?9)*`$@L``1K8R_).0
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M@K(IIE4-_:F)T_#_`++X'E?$L%F+>6<YFYNPUY`'4%K'XMK:2:$;*J8?4+$E
MQ0DD#U0>>Y5]X<UQCE6;Q%S%",3;6Y6UFV,:7AM$N(XI3NHPE.]5`"DG:!V8
MB0GFAS'TGCSQ'QS2<^KE5L&V<@+K@^-T(EI!^A0H+0-K01,%DLC-@\1E'%>@
MTD'2A6J+@BBBGE$%3P^,>O-N#<)Q?).97V+R4LT>!QL%W<S>70S/#:GV$)!4
M.U5&XB@%32M->B<RYCDN/\1LLE81Q/F\A+;6\6\'REFN%W;G`(;8-K=`>]*F
ME=8^#O)K=KSMG+'B5R96SNR:[Q7DLL>AI>5P$U5*E?Z=KU27M4(LXJ\W+3KB
M"L,"=L=NY*1T=%8IB&(4!*8QUY[Q3C^/P.'YEQ87,6&RZW`\BX=9)(9+:01M
M2150,CUJM14=:GJ`$X1RC-7^=R_$>1^1)EL4T!\Z%61)4N(S(OJ,S$,E*'L#
M6@'JEF.WM^<E-&Y-5/DE-:0E6TGF4<RM_P`'JP5J+=1:)Z-F<I"LZXI*D=24
MD9W.G2?J>I<$,DFJ/;PI$[?&C]Q^+8SBMYBX,692EY@[2[DWL&/FSAR^VBK1
M/5&T&I'I.KGV^Y-D>3VN3FR0C#VF9NK5-BE?Z4)0)NJ35O6-3T!Z=!IF'+CG
M1S`B=WY<T/BXUQ&`IO`/`ZGNFNGUR!LMCFMAD+179&]IT6JK0-C@4:?%MZ=%
M*E%^<CA89#L7X)F`0[CAOV_X9-Q[#9#EAOY+[D>1DM;;X=T1;81N(?-DWHYD
M8RL/5%!L_$:X[EG.^5PYS+V7&A9QV7'[!+FX\]'=IRZ>=L3:ZA5\H-U[[Q[0
M#"CA.1WN"R^>>WCF_,/+Z-'RMWW:&PECE]/MKITG7XBZ;XX@&4.6V.V'IGKF
M%K"LRHHOY`HG=^G`A3I`IXR\UQG[<09'[E77"LO<,F/Q\ET9Y(P-[16F\MY8
M-0&DV@"M=M22#2AZ#/\`/[BS^WEMS#$P*U_?Q6_DQR$[%DN`"-Y%"50$]J;B
M`*J#4>\">4NOZIJO(_C_`+;J?&G9+;A$E"H%NV`*3=:DB/'#R7@[E4K]EUB>
MS$A69"G6N&59-WR3PZ$B0IA\!#$$3'W#XEA<1B,9R+!6F4LK/((Q\J[VNM**
M\4D,Z!0XEC8,4*@IZ2#T=P3E&7RV4R."S-SCKNXL7`$EJ64U!*RQRQ-4JT<@
M*A@:,/"O4J-PRY+:/O6L\[J5>DJVG#<<N4,AD&>&@HMU'O5:DVJ4%-I'L2[B
M2?DDY?UDBH`K)$;D$G8/+[AW',YQQ;&<>P_'[['F4SY/$K<S;V!'F&1E.P!1
MM6@'0U/XZT^'\DR&=RF:L[T1B+'Y%H(MH(.P#INJ35OQ%/RU'9[?'N"\J.6N
M[MJM;M;QJ*A8W0=@C9[)XOBSNC6:>TO.IR:@F2\9R`4L+O'V\VZ%-HY.@8RB
M_A*HCY0*CV#TO[D?;CB7#N/F\L[.^>=K:W9+AK^U*B6958AK38+DJ/6%:`=C
M6FO._M_]P>3<LS@M+N[M%C6:4-`MG<ABD9(JMR28-QZ&FXGPI4@$W^Y1[B/)
M#BIR)K]`KCO/,/QC^649<8C:=AQ+7M4SK4M&>V)Y'/\`+IBW9<[*.514)$-D
MEW+_`-'(/""X*<4@2,GXJ7VN^VG&.7\:DR-RMS?YSXMHVMK:ZMX)H(0@83K'
M./Z[,Q(5=R*:4K4&EK[D?<+D7%>01V-N;>RP_P`,KK<7%O/-%-,S[?)+PFL2
M@=6*JSCN:*5TYO\`XB-0_,%P(^WRT_[B]<M_]9WORWD7_P`2/WNM_P#^R+/Y
MCQ[_`.7)[K6KH?M$\;M4U_5M2O-]Y"2M>W"_572-:PEIIZ4'AF@V.E,XQG6B
MVRI0E=CYB;BXPD4F<K=>3,45!$1'MV`'8W[S<GQ&%L\1C[?&I<V%O)#;W9@+
M7<*2DE_+D9RJLVX@D)VT_(_:/CN6S-SE;^XR+V]Y,DL]J)@MK*T?L>9&J!F"
M]P"_0FH/04D!U_):OM./:-B%F/(Q=-TV@67-YP]:6:QLJPKUH@W5??#!KKLW
MK)B\;,'9O3F,W533,!>Y#`';KSG"YF[P6;M<_:[7OK2Y2=-X+*7C8.-X!!()
M'7J"?3KOLSA[3.86YP5UN2RNK=X6V45@CJ4.TD$`@'IT('HUASW(*QFN)TW!
MH%U,N*=1\S@\JB'LH[;.+`M7*_66U59.7[U!DU:+2QXYJ4RBI&Z:9E>X@F`?
MJ]+DLU=Y3/3\AN`@OKB[>X8*"$#O(9"`"20NX]!4FGCXZ3&X:UQ>#@X_;ES9
M6]JENI8@N41!&"2``6VCJ:`5\--"IOMA\:*-:.&UXA0O`W/A!4)BA999W4W$
MGE+-4)>)EXHL'I)T:\@C86D.>>>.F/I21YFSERJ(")%#D'M+[[K<IO[3-X^?
MX?X'/3++<1A6VI(K*V^"KDH6V*K[B^Y5'B`=<E:?;+C5G>8C(0^=\=A8FCA<
MLNYT8,-LU$&X+O<IMV4+-W!IHX[;[>/&'DGLC[:=]I@ZY,'R=OD%>JEV+$R]
M&H\*2<E+`\LM.AE(DKR)O4D^E!*K)F=*J%113(D5,"B(TL#]RN5\7PBX+CL_
MP<(O#<O)%N665MBH$D;=1HE"](]H%22:ZMYO[><8Y)F6S6>A-W,;06ZQR4,4
M:[F8O&M*K*2Q]>I-.@II6N/W&FC<=^.U1XQU^5METSBF5F6ID:MH<C'S5B=U
M:5=2:PPDI(QD5"-7;-BSE#,VX`W()&::9!$PE\0XW(^4Y#DO)9N57"0P9.>5
M96$(94$BA1O4,SD$E=S>L:L2?'6O@.-67'^/1<:A>6?'11O&/-*EBCECM)54
M6@#%5`444`>&B+PGX0XOP)RB6Q[#S6IS6YN[S-]DY"ZRK":L+J8F&45&>0I(
M1\1"HFC8R+A6S=JF*(F(0@B8QC&,8=#G?/<[]P\PF:S_`)(NHX%A58E*H%4L
MW9F8U9G8L:^/8`:H<*X1A>!XI\1A/--O).TK-(0SEBJKU*JHH%0`=/2>Y.FU
MVKV<^'-P;627EXNXCL-FW9SR&<\CF\C6T]WC[PO=D[PA&1%R/5%6S.FQSQ$C
M1M&"S.FFS(!?$*H>;UU%I][.;6310PO!_LL6/%F+(J_PC1"+RB6C\P$R,/69
M]U2WX=-<Y=?9_A]VLLTJ3?[O+>FZ-W5/B5E+[Z*Y0@(#[*[:#N.H!T[_`'3B
MKF?(ZVXK8=96G[)7\/M4K>H7,%W$6?-+?<GL$YK\1/Z%7740Z5LR]/;/W"T4
MCZA!L@Z7.HHFK^J`<7Q_E^5XQ9WUMAQ'%<W\*Q-.`WGQQAP[)"X8!!(0!(:$
ME0`".^NNSO%<9R.[LY\OOEMK*5I%@.TPR2%=JO*A4EC'U*4*@$FH()&OGBAQ
M9HW#O*OY*YC9+Y,YU'VBRV&H0E[FV,^>AQUFD5)=Q2ZL^:Q$4Z2I\;(N%E6;
M=T9TNB*YP%8P"``<PY;?\UR_^^Y6*WCR;1(DC1*4\UD&T2R`LP\QE`#%=H-!
MZHT<5XO9<0Q?^SXV6=\>LK/&LK!O*#FIC0A5.P-5ANW-5F)8UTYCKEM=+IN7
M%7C#GW$#'8S$<QD+3)U*)L5SLS9W<I%A*SII"\VB4MLNFL\C8J&:F:HR4LJ5
M`H(`8B(%`QCF`3#TW+^5Y+FF;?/9984O'CC0B)2J4B18UH&9C4JHKU[]@.VN
M<XKQC'\0PR8/&-*UHCNP,A!:LC%S4JJCN>G3MWJ>NFMXU[8E%P735="S7DWS
M%@X-]K5FV6:QI#8(EOBMBM5OEW$S8&T]2&%)9C(PTBY7`JB1G(*G32(!E!$O
M<>NSGW6R'(<4,;E,5A)+A;-+9;DVS&Z2.-=J%)3*=K*.H.V@)-!KE</]L++!
M94Y/'93,I"UTUPUM\0HMG=S5@T0B%5-`"-U2!U->NE%Y3>WYDW*:]U36'][V
MC%M<J=0F\X2T_`[X6A6^;S.R.#.IO/[&Y<1$XRE*ZY<++*I`*!'#998YTU"B
M/69Q'[CYCB./FP\=O8WV&FF6;R+N+SHTG0469`&0JX``/4A@`"-:/*_M]B>5
MWL64DN+VQRT431>?:2^5(\+5W1.2K!D]9B!0$%B0>VC;,\'\,D>&;_@E$,[%
M4<*?9PIF)4J],D&V-(-PX]:_D49Z;93)%Y^3DCJ.G+E=!8%7"ZAA)^MV"C#S
MS/IS=>?SM'-GQ<^?ZZ_TRP%`-BE:(JT55!%``*ZT'X9A3Q(\+@#Q8;R?+]4C
M>!NWEMS!@69JLQ*D$D]-;M,X;Y=1M^J?(Z)EKLXO5-XQU_BA%,9&7C7%:4S>
MMV-.T,9%XP2A4'JMM5D4NRKDKDC<R8B`-RB/BZ;?<WRV0XY-QB9+<8^?+/D&
M*JP?SW3RRH.XCR]O9=I-?U:99<+Q5AR&'DL+SF_@Q:6"@LI3R4?>&(V@^9N[
MMN`I^GQTD^W^V9QMY"1/*B'TD+M(-^6MARRVW==I,Q#=Y3+1CU89U*FSN9N%
M:^Y&OOR1302NA<@_*X!=9,0!)4R8[&!^ZG*..2XB;%^0K8:*XCB!5B)8[F0R
M2).-XWC<:KMV;:*>X!UF9C[9\;SHR@R/GM_NTMO+)ZR_TWMD$<;0^H=IVBC[
MMVX,P]DD:6S=^(V/\C./[7CCI;:P.*7%-J<:N3L'-&A+U5)^@"S/4KE6;(U;
M",5:X9=D4Y'!413-XU"'3,DH8@X/'^9YKC/(SR?%F,7SF3>CKNBD2:OF1NA/
MK1M7M6HH"""`=;><XCB.0\?'',CYGP:+'L=&VRHT0`21'`]5Q3O2A!((()&N
M+Q5X:YQQ.)I$K6[3IFGZ1L<_%6/5]BV:V!<]*O;ZOQ@PM;;2\NA'Q$>C%5N*
M,9!DV;-44TB*&$?$(]^I^7\XRG,#:PW4-K:8NRC9+>VMH_*@B#MN<JI9CN=J
M%F+$D@=M0<4X9C>)BXEMI;FZR5XZM/<7#B2>4H"$#,%440$A0%%`:>BB1XK[
M<%&P+:K!L6=\A>5C".MFJZ'LEGQ-?5(K^1-@NNF#(FL+J7H;&G,3O4$E7R:C
M;QNQ5(=DV$ZA_+^.UG?N?D.18*/"9/&X=I8;.&VCNA;M\6D4%-@64R&A-"&H
MM#N:@%=8N$^VMCQ_.29K'9++K'-=RW#VWGK\*\DU=Y:(1BH%1MJU?56I-.N#
MD[[8F"\H]+G-3L-RVW,Y^_46.R[:&&-Z&-)@MTS:*<J.6%/U&/-$2AI9DW*I
MZ<%VJC-V+/\`L!5$@%\+N*?=;D/$L5'B+:"PNK>WN#/;&YA\U[2=A0R0-N7:
M3WHP9=WK4K6KN3?;+!\HR;96>>^M;B:$17"V\OEI<Q*:A)U*L&'0*2-I*@*3
M0#3A=GXD89NW'-?BO=*J=KCY*]5Z[`1%9?KP<G3&]'&./29"H2Z7FN(B5JBT
M0V.S6[*!_9>%0JB9CD-S6#YEG^/\F'+K&;=FC+([LX#K*9=WFB1>@99-S;AT
M[U!!`(Z',<2P>;X[]+7<6W#B-$14.TQB*GEE#UH4VBE:@CHP*D@I9Q;X#9QQ
M9T70-?B=/W37-2U.K5NHWV\[?>F5UFIZ,I[QXO6E#':5Z$3:.(MF\](7R@*F
MHBF4QR&6$ZI]?EOW$R?+L;;8::TQ]EB;25Y(HK6(Q*C2`!^[M4,1NZ]02:';
M0#*XKP''<5OY\K%=W]YDKJ-4EDNI1*S!#ZIJ$6A`HOHH!TW5)5W#>,6?X!<>
M0EWI<A:7LOR4UESLE\1L,BP?,6%I=0T?!J-:RBSBHY6/A0:1I!!)=1TJ!Q$?
M,[=@#%S_`"K(\CLL;87RQ+#B[,6T6P$$QABU7)9JM4GJ`HIX:V<)QJPP-W?7
MEFTK2Y"Z,\FX@@.>X2B@A?P)8_CIL''WVRZ3QHO<5:\UY-<Q$:G&7:W7P^)2
M>P12N(RDS=W<Q)3J,M1H^E1I7;!:5FE'92>H*?U*::ACF$![]9R3[JW_`"G'
M/9Y3%80WCP1Q?%+;-\4JQ!0FV5I6H0JA:TIM)``URN`^V5GQO(I>X[*9GX5)
M7D^&:X7X5F>N[=$(EJ*FO?N`2:Z[W)SVWLMY0WBR76P;!R4SA/0J7'9UKE+R
MG65Z]G^L4B+%T#6#MM4F(BQ1[8?(>J(*.8P(]PHB<P&.)C"?JOQ3[GY;B=A%
M86UEB[HVT[36\MQ;[YK>5J5>.160GJ`0'W@$#I0`:L\G^W&,Y1>O>7%YDK99
MXA'/%!,%BN(QV65&1P13IZNWH3XLQ)9_X._MR_EIK'_WBT__`)OJW_\`=OW/
M^:R_^F/_`-FJ'_TQ]M/E</\`ZG_]VI,^O*M>HZ0#..5?&G7WVC1N7[OE5\>Y
M"JY3TU&LW>!E`I!&?JO5O+"JW>F18QC86*X'=F-Z4ID5"BIW(8`W,AQGD.*2
MWDR5E<P)=`>3OC8>96E`M1U)J*+WZCIUUBV/(\#DWGCQ]Y;3/;5\W9(I\NE:
MEJ'H!0U;MT/7IH,N57&]_1+SIR&V9PG0,R29.-!M3VS1T;$TYK*QK*8A'=@6
MD56IXUG8XF2;.HM90H)R;=RDHU,L10@F'XSR!+V''-9W'QUP2(D"$M(5)5@M
M*U*,"'`ZH00U"#H3D>">SFR`NX/@K<`R.7`"`@,I:M*!@04/9P05K4:S17*'
MCQ/99`;;`;'09[*K7((P]7NL'/M)B*L<XX<.&J5>@2QIG+R7LAG+18GT<W24
M?`9%0!2#P'[)+QO/09)\//:3IDXEW/&RE610`=S5H%2A'KDA>HZ]1IT?(<)-
MCDRT-U"^.D;:DBL&#-4C:M*DO4'U0"W0].ATIM9OM)N=,B]%J5MKECH,W"EL
M<3<X:982%8D($Z!G/TPVFVZYX]2/*@0QC*^9X"`4WB$.P]LZXLKRTNVL+J*2
M.^1]C1LI#AJTVE2*UKX4U?M[RTNK1;ZVECDLG3<KJP*%:5W!ATI3QKHI4?=L
M@TF2;0U'T&NV*7?0JUFC(MH[,G(2]6079-C6V$9NTF[B:J1W$BW(G*M"K1ZI
MUB`18PF#O:O<+E<?&9;V"2.)7V$D=%<U.QB*A7H#5&HPH:CIJM9YC%W\@BLY
MT>4IO`!ZLG0;U!H62I'KBJFHH=*SUEZTM#HT:'1HT3+WHE&S&K6.[:#:X.GU
M*GPREBM-@G7Z#&-K\`@<Q%YJ7<*F`&,4@8AO,<*=DB`4PF,`%$0MV5A>Y&YC
ML[&)Y;J5]J*HJ6;P51XL?`#KJK>7MI86[W5[(D5O$NYV8T"K_P`Q]`_'MKO0
M4Y#V:$A[)7I)G,P%ABH^<@YB.7(ZCY6'EFB+^,DF+E(3)N&;YDX(JDH41*<A
MP$/@/4,T,MO,]O.I2>-BK*10JRFA!'@010C4T,T5Q"EQ`P>%U#*P-0585!!\
M00:@Z3*S<@L4IE@DJO:M+JD#-0GT26>0D9$J#6O.)\I#U^/L<J)1B:_+6$BI
M#1[-ZN@Z?`JF*":@*$\6C;X+,7<"W-M;RO"^[:0.K!?:*K[3*O7<R@JM#4BA
MUGW&:Q-I.UO<W$:2I3=4]%+>R&/92WZ58@M44!J-*Z"Z!EU&Q5DC.44D5U6X
M*$%=)!P==-NLHD`^81)=1JJ4AA``,*9@#N)1[96UMNZAVDTKX5%*_P"51_F-
M:=17;4;@.WY]O^!_RUEZ32Z'1HUB3706.NFDLDJHU5*@Y(FH0YVZQD$7)45R
ME$3(JF;.$U`*;L(D.4WR&`14J0`2"`14?CX=/X@C2`@D@$5'?\/'_@:Z)%YT
MZA9L2%&[6:/@E[(_6C*['J@X>3$^_:LU9%XVA(2.0>2\L=A'-U'#D6Z"@-VY
M#*JB0@";JY98Z^R!?X.-G$:U<]`J@F@+,:*M20!4BIZ"IU4O,A96`3XN14,A
MHHZEF(%2%459J`5-`:#J:#77J-RJ=_@&=JI%DA;;6I!5\BQGJ](M9:(>+1C]
MS%R*39^R46;+*,)-DLW6`IA%)=(Y#=C%,`175I=6,YMKR-XKA:55@585`(J#
MUZ@@CT@@]CJ2UNK:]A%S:2)+;M6C*00:$@T(Z=""#Z""-<B3U'.H70ZKDTM=
M:Y':9>(*Q6>H45W*-4;-8Z_45(Y*S3$1$G.#IXPA%)9N#A0A1`GFA^@![2QX
MZ_FL9,G%#(V/A=4>0`[%9Z[%8]@6H::8]]9Q7<=A)(@O959D0GUF5:;B!^%?
M^/H.CL@X0=)^<V71<)>-5/S4%"*I^8@J=!=/QIF,7QHKIF(<._<IRB`_$!ZI
ME64T8$'_`,^NK08,*J01KDV6SUJF0<C9KA88.J5N(;G=RUALLLP@H.+:)AW4
M<R,M*.&K!DW('RG54*4/TCU+;VUQ=S+;6D;RW#FBJBEF)]`4`DG\AJ*XN+>U
MA:XNG2.!15F=@J@>DDD`#\SI/W^]XS&9_5=4=Z150SV]DBE*/:6\DF]CKF6<
M8K2D0%3!D#AS8U)");*O$R,TUC&9HJ+]O*3.<M^/!Y>2^EQB6\OQ\.[S$(H8
M]IHV^M`E&(4[B/6('<@:I/F<5'91Y%IX_@IJ>6X-0^X5&RE2U0"PV@^J">P)
MUKV;D/A=.AZC8++K-"BH&^Q8S].FEK)&JQ-@K2:,<X<6N/D&RZ[0]09(S#,S
MF7,<L:V*[0%5<GG)^);?`YJ[EE@M[6=IX&VR+L.Y7Z@(017>=K43VSM:@-#I
M+C.8>UBBGN+F%89EW(VX49>E7!'38-RU?V1N%2*C2QE,4Q0,40,4P`8IBB`E
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M-CNGD)54.^1E5%#5\I5[;B%Q\;%$./\`;N7O-KE.O2'.!9_B'%[CS5[%`Q,P
MZI'(73./U==PJ^B9E!VR*;R<R4+#)IP<._3;KM5'AG0LW2[5L+HR\@5LY:XK
MA_&A,,W/>7ETZ,RB2UAN7#>5,R,0OJ`R2+4,%V[U#-MT8%EPUQD^5\B\DX:"
MTM;9'56*7,MNNWS(E=06]8^7&P!!8ML8JNX\#'\QPR<XM8_R$X[[M24%N-/.
M/0N5][]=4-`@<;O.F:/"RRV@8AF%?/78V\O!I]0O3.%K2T;"O%7;QN!2-#*N
ME$T9\KD<S#R2ZP6>LIB,AAHK*.DD33QQ1,HBN)FWF,>8\;22AY%"J>K44$PX
MJQQ$O';;-8.\AW6.6DNY*I(L$DLH)D@A7:)#L1UCB*QL210+5B`\KA?A<EAG
MM-W"C<KH2TUJ)N5+Y'W_`$O/8?S1MV;YML4M=;0^HT2V;^H6:V2!J%@,8S1,
MAU&\BH=#P&4*)1Y+EV:CS/W/BO>,O%)+#-:Q0RM[$LL`C02,32J-(OM'H4`:
MM#KJ>*XB3$_;>6TY&DD<4L-S)+$OMQ13%V,8'4APC5('4.2*5TRN'O7-WA]7
M-3S+/=.H//&I4'A#N&B<3MQAZTPDMMQ!.F)4IK$4/48V(4>1]D8V%H=JK&(.
M?-=R[N`\`%\#99NGU\MEP[E<]MD;^VGPEU/F;>*]MV<BWN/,\PM)"6H4*G<'
M(HJ++6M6#'E(KOEG&8;C'V5Q#F+6'$SRV=PJ`SVX3RP(Y0M0P8;2@-6=H_0I
M4'V8U[E3*\)=&Y6<?>5J6NP65S&&;]&5"ER*]YLK_,(&F01N4.*:'<K%367C
MG9<T<_L3=@T0;RU9<**,`%-N=JF%&+%<:CYA;\9SF,^%GN4N;8O(/+03-(WP
M=Q%&DA]5:K$68E)@`_5@QU<DR?(I.)S\CPN2^)AMVM[D)&?,8Q+&OQ<$LC1C
MUC1I0H`>(U3HI71RY1\BN056LW%J$D-=F./6;<MZ_P`EKXSTG1IHE0BLITJ7
MJT*\XPY;:+/&UJ63@4*C#21Y1Q!.S^3/SR2K)9RHV3\DU7C>`P5S;9*:.U2_
MR&+>TC,42[VFB5V%Y,B%UW;V&P2+UBB(<*&-19Y#G,U;7&.ADNFL;')I=2"6
M5M@AE9`;2)W",%"*=YC8TDD!0L5%--CY9<M>6F>V_E@FWY,V*/E\%ROVU;Q6
M8JG1T!`4R9T?5;O`5_;G*4!/5E2W.:?9(I9=PI!.UP]$BZ*=8A!(7MT/&.+\
M7O[7&;L=&T5]<Y:-VD+-(L4,;M;C<K[!(C``2*/6*T!-=8/).2<DL9\B5OW$
MMG;XQU"!5C:69T6<[67?L8$GRV/JU%1TT;^54E(KZI[]#"P:-<9!&,X/Y/\`
MRWI<U8TU8![5+'CNB2,J6MP2C0AW4'#7&95*U48G*FD_DE2*F677+VJ\9C08
MSA+P6\2ELS-YLBIZP=)X@N]J]&:-14-U*H"*`:L<BDD;)<R2>>5E7$0^5&S>
MJ4:"0G:M.JJ[&A7LS$&I.G0^UAJ^AOMNV;"IK3;!>LVHO%'@3?*%#6-U$/OX
M2G+UC!AO<=6G$;'1YFL%ZMDS\;'^T(S5`!_5.J83\Y]RL98)A[3-0VR09";)
MY*.1D##>L=Q_3+@DU:A;UNFX?@.G0_;K)7SY>ZP\MP\UA#C<=)&K%3L:2#^H
M$(`HM0OJ]=I_/JA?)]GI.,:UR<Y)<0MDK.B0=DUF$K_*_P!O';88DE_-BZ1[
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M1F^VK852&V/T&(M-0HXM:GG);:K(V)G#OO-^G)$/1KO%&X*)J96`Q>#RT64N
M(L9%)?XJ6&-+:)6>26W^)D,\K(\E7EV;8FD6GEIZZH&H1HYS)9K%R8R"3)2)
M8Y..9VN)65(XI_AXQ!&KI'1(M^Z54:OF-ZK.5J#TH;D5RGL/,T,,NW(>C9Q;
MZ3"<([5GK&4C;/6:=R9I%@KSA7E&]H6=?PJL[N<I=[&_59(%7=(.Z<#)HJDD
M0I7JAHI<!QJ#B7^\V=A-<6LSY!)2"CO:2*_^C$LN\",1H`QH"L^Y@2?4&I8<
MYR*;E7^T7E]#!<Q)8O$"&1+I&0_%F.+82YD<[14@P[5(`]<ZZ'`'DQG''^M<
MEI?D7LU\4L.@^Y[LN"0S6Z&FK>[86"1L9(;,QG4(>!7=5)&>KT0DW!^_%K%^
ME9-P1\I(I0%G...Y#.7&.BP%I!Y$''(+EC'M0%0NZ;;N8!]K,3M6KU9JU.G\
M,S]AA+>_ESEU-Y\_()[=0^YR&+;8MVU:IN50-S42BK2@TY#W$LO'2M+X[/\`
M,.33OB?ROS2'UFYX7HDY'L)7*;-".AHL)H^<:,PEQ^BW#:P`XB542'\:PI-E
MSI(N/+.4G/\``LC_`+?C[],CCAD^,7#P1W,2DK,C#S&BEB*^L"M'!\*E066H
MKN\XQ_Q]_8OC\@<;R2W29[>5@#"ZGRUEBE!Z>MZA%:F@8@-3HPW\8_)6`B>#
MTYI$K#<?&>EM?<JJFS!G9(QMD&I:+E=-M,KEFKT61FXR1>-C:;?TW$["%;.`
M^G%UC'2(Y043*/:_2?'IY<S#CU>_>W.)>#S:F>&*:1!-#(%(!\F*D<E1_3`H
M2K`G7&_5&>@CQ$U^R62W`RB3^50032PH[0S1E@2/-DK)'0_U":@,"-</,.4O
M(?1_^'(><UB>D+5N'ML<L+EH4E&P]-;VZ0U*N5Q@XK,Y"R+2KC,5:S%ED5NS
M:.,V1=K,2`HW4,V#PS9'C>!L/]_$-JBVUGR"RCB!:38(7<AU8%]KIM(ZO4J&
M-&`;26/(<U??[(9+EFN+O!WCR$!-YE5:HRD+N5JCLM`Q45!II)\:Y%;#4>,G
MML9?$<AULFHVZ\8MND7F\WRX*LH&O<M647!IT&F6FYH5V9.DVJKUX_ERU>1.
MD-AD3F:NUE1)Y0ZF6P&*NN1<@R4M@+J]LLC;@6T<=6:R);S9$C+KU<!4\Y*^
M4M&4"M=9>,S>2M,#@L=#??#6=W87!^(DD]5;P`>6CR!&Z(=S^4Q'FL=K$]M3
MT<JE%GGMZ;POI3VMS,ZXXDZ*I89+Z*4B:_*7!?(9@'#Z'A;"DF^C$I">4$[%
MJX(5VB)R)B`*AVZ\3XR`G.[)<>)$A&4BVC=N98Q.O1F7H:+[1'JFA/;7L/(R
M7X1>&_,;S'&2[C3:I<PM4JK=15O9!]8=!WU$I1B2S/./_P#/GICF009X_0*+
M;(71+&Y>)-ZU4KI8N(LA#4M6U2*JI8^%74<Q\M&HJ.C)>4]<>F[@JL4AO4+P
MQ/D.=8Y5)RL\R-$@%7>-;X-)L'=NA1R%K51N["NO-K,2K8<*OV8#%PPNLK$T
M5':S*Q[SV7J'45I1CM[FFH^,[SK7\ZXYPBFO14[$PU^]C_F+0,CC)U@]:+N[
M39]ZD+9`YM$LG:9%E[M9*'9JZNPBDR^N=-/*322,#<Q4^\O[_%7^?<8ID>:#
MF5A+.5(-$2V"-*Q':-)$E#.?55JDGUNO$6-CD['!(<FKK#-Q&]CA#`@EWN"Z
MQ`'_`+C1O&53VBM`!ZO2VSQA@;A5N-?'RLZ$#DM\KN(Y5!W0CTQC/4[5$T:"
M86!-X<YC&4=IRJ"I53"(B90!']/7R[R.>TN>0W]Q84^"DO)FCIVV-(Q6GX4(
MI^&OI;C\-U;X&RM[ZOQB6D*R5[[Q&H:OXU!KI<NL76OH=&C0Z-&ODQ2G*8AR
ME.0Y1*<A@`Q3%,'8Q3%'N!BF`>P@/R]`)!J.^@BO0]M:7T5%^6JC]&L/)73%
M%=+T;?RUD1[=TE2>7X5$Q[!^J("'3_-DJ#N:H_$Z9Y<=*;5H?P&MA5JU73(B
MNV0613$IB)*HIJ)D$@"4@D(<HE*)2CV#L'P#I`S*:@D'3BJD4(!&L18]@44!
M*Q9E%JH=9L)6R("W54(*:BJ`@3^R4.F(E$Q>PB`]A^'2^8YKU/7OU[_GI-B"
ME`.G;IVUCEI)C#1C^6E%10CHUJL^?+`@NY%%JU(*RRWD-DEW"OE)D$W8A#&^
M'P#I8HWFD6*,5D8T'4#J?Q/322R)%&TLG2-14^/0?EUTVW-.6_$K29JM1.8[
M1ETY,ZD$U)TM*(E&3)72CUU99K8W%2<N$F:5V=P2R"A'H,3NE6HIF!4"^$>W
M09'BW*,?#)+D;2Y2&VVB3<"?)W]4#@5\L-4;=U`?"NL&PY+QJ_ECCQ]W;O+<
M;BFT@>;MZ,4)IYA7]6VI'CIS"#%DU;BS;,VK=H;SA,U0;I(MS"X,<ZXB@F0J
M0^<<YA/\/UA$1'OWZYUG=FWL26])/7IVUOA$5=J@!?13IUTG>D:AE&;*49AJ
M5KK%7'0[Q"4*@(V=5%!&RZ#+&4/7JS"F<)G06L4@=N<6B(""J@IF$G?PCVOX
M_&Y/("9\;%))Y$+22[.NR)?:=J==HKZQ["O75&_R.-L#"F1DCC\^98X]_3=(
MWLHM>FXTZ#N:=-*`K%QJYSJK1S%950>YU%6C=0YQ$H%$3G.F)C#X2@'Q_0'5
M$22**!F`_,ZNF.,FI4$_D-)XWTS))359G%D+/5G6O0=*C;G,T(QD!M+.@/)4
M&$78%F*J0*J5Q2:/Y*2I1,B#D#%#L<#`%]L=E(\8F7:.48IYC&LG7890M2M?
M^?;U([TZ]M45R&,DR+XE9(SDTB#M'^L1DT#4_P"7=T![5_'2C(,&+4XJ-631
ML<2B03H-D43B01*(E$R9"B)1$@?#Y/@'6>SNW1B2/Q.KZHB]5`!_`:\4CH]9
MTU?*L&:KUEY_HWBC5`[IIZD!*Y]*X,054/4`(@?P"'C`?CWZ422!2@8A#2HK
MT-.U1XT\-(40L'(&\=C3J*]Z'PKI+M,US&\G<0*6EVNLUV8O+P(>K0KQ/Z0M
M=T>1A#/3L:Y6(UL_LMF-$)*BLJ5HV7!H0PJ'\!1[]:6.Q>6R:N<=%))#"-SL
M.B1@]*NY(1-W8;B-W85UGY#)8K&E/CY(TEF.U%/5Y".M%0`N^WN:`T'4TUUJ
M5?\`+]4CY3^"+#6;@QJTLA#SK./.W=&J]@;LV<LE"S<8JF5Q`3S)B];KBT<I
M(ND"*IF,0OB*(Q7ECDL9(OQD<D3RJ64FHWJ25W*>S*2"-P)!H>NI+2]QV11O
MA'CE2-MK`4.Q@`=K#NK`$':0"*CIHQUV:J=WB("[U>1@[1"2\:G)5FT1"[.4
M8OHF32(HF\B)5N*J:K-\CX1\21_"<.W?OU7N(;JSEDL[E7CF1J.C5!##P93X
MC\>VK$$MM=Q)=V[))$RU1UH00?%2/`_AI$]$T;C2\O$+BFA7BD(W*7MU*D4:
M(_E46AIFY&]79,[B+$5/P,E9R75J1Y"'BWRI'$I]%^-!%=-$P=;%AC^0I9OF
M+&&8VBQ2#S`M=L?1)63QVKOVR.HHF^A*DZR+Z^P#WB8F]FA%T\L9\LFFY^K1
M*WAN;9N1&-7V5`(&E/M-[S2)M%/S.X6&L-[9IR5B/3:9,K-%)*WM:7')SMG7
MCHIP50SQE76!TUW*@E\I'QD[B!CD`<ZVLLC+;2Y&TCD-K;%/,D6M$,AVH"P[
M%S4`=S0^@ZT;B\L([B+'W3QBYN`VQ&I5Q&-ST'B%'4GL.GI&F_YASJX2;E<$
MLYR?D?BVD7.-9RLXG6*O:X>8D8V/K+<XR\OY")CD8-(=L<P*+B)")E-V\7ZW
M8=O(\,YAAK4W^3Q]Y;VC$+O=&4$N?57\2Q[#QUBV'+N*9>Y%CCKZUGNE!;:K
M@D!1U;\`!X^C2GPN[\>)K/[)KU>T[,97,Z))34-8M%AY^">U&#E:\Y*UFH\U
MD9K*1IG3%^]!`Q$53B9RKY1?$H;PCG383/0WT>*GMKE<C.JLL3*P=E854[#U
MH0*]1V%>VM"+,8.6RDR<%Q;MCX696E5E**5-&&X=*@FG0]S3OHY4:VYOIM;2
MFZ))5^SUUE-R<>8T>@D)(:SP,DNUF8N1C'""+N"LL)+D4(Z:N44'C9QX@4(4
MW?JI>VN0QUP8;U9([@H#U/M(P!4@@T9&6E""5([&FK5G<V&0M_-LV22`.1T'
MLNI(8$$55U:M00&![C1Z7;MW28HN4$7"0F*84ETB+)B8A@,0PD4*8OB*8.X#
MV^`]4E9E-5)!_#5QE5A1@"/QUK*1<8JT4CU8Y@HP6-XU62C1N=HJ;S"K>)1L
M9,43F\TH&[B41\0`/R].$D@?>&;>/&IK_GIICC*["H*'PH*?Y:SN&;1WY'JV
MK=SZ5PF\;>H026],[1`P).D/,*;R7"0''PG+V,7N/8?CTBNRUVDBHH:>(]!_
M#2LJM3<`:&HKX'T_GK8Z;IVAT:-#HT:'1HT.C1H=&C0Z-&AT:-<&TO&K"LV%
MZ]=-V+1K"2B[AX[72:MFR2;)8QUEW*QTTD$DP#N)C&``#Y1ZGMD:2XC1`68N
M*`"I/7T:@N65+>1W("A#4GH!T].J>?#I616S_P!E(A2?SX&L\BMI.GQWKC%Q
M!V[&7<CI%U!3D5:[!!*O952M4ADZ]2=A.)1\8[2=E$IE!*`]?5G+!&+[EY/^
MB\RPM_\`5.=R7`$4?^E16HN^0BFZ,LZD>&OF/BAD-AQ4#_6;+V?_`$RC:\-9
MG_U+LI+;8_:VN%4@^(J=/GP/D]R5T;'.36I6WD6VK.I9MAG-)GLN!K?Q$&@9
MAL-+M]CEL.M<%!24"VKV70=5K#-M%,TB&=-+6@Y266,X?)K=N,S?'./6&6QV
M-M;`R8RXO;`P7/J^5-!(B+<(S!BTS.Y+L31H2"!M0C778?/YZ]Q60R%U?"/)
MP6=]YUO5O,AF1W:!U4KMB"(%114B4&K;G!H3=O<ZU)<0/:[WZT:K==]US:>5
MOM]Z*-%T"?J]9I,5=Z_G%T/*,*V,+5FAZ+'6>P2:)+$\>>N*W>%!8Q4A[I#;
MPZXN/E7),';6T-CBK/&9.+S(E=Y&C:6.A?<Y\PHH/E*NVJ].O?53+MDI.,<>
MS5Q<RWN3N\EC9?+D9$C$BQ25"[4'EAV($K-NHW6@[:.%DYX7BPY1P_E`TN[9
M1`:+O6[9?S7L&A6:5KCOCSN$12;`E1<CF;U6X)T\H68-M'6*I!O2$`LK'QC-
M-Z],5=^8]6WX596^3RL?P\-U/;V5M-CUB0.+JW:1?,G6-V`DF,0I(I]AG<HG
M1*6KCE]Y-C<9)\1+;0SWEQ%?M*Y4VTXC;RX3(JDQQ"4U0CVE10[=9-)/MFI\
MD,@W#>-)IUP::KR9I_LMY.*VC4NH.DT;38T.0I`N>D5BDR#%15&3:TAXXLJ+
M!1L<A?"58$#-C$*;3P^-X_E<-98^[B-MQV7ET_\`2D<>HGPO].)Y`>H,@$18
M-7N-VZIUG9?(9S&YJ]OK*47&>CXK#_51/:;XGUY50@=1&3+0K3]6W;0:<K?M
M5Y*0?$^:Y?8/R9<[OG6,\@:-MB5*SR0G;>XMW%=Q$TX-DPZSW>X5QO-7&T5M
MR1[.M720MI*(35<1C@0\!$R<]98SCTW)TXKF\<+*_N[&2W\R4+&$O`TGD7"1
MQN51'&V,@U1R%D7Q)W[S)9R+C3<FPU^UY96MY'/LC9GWVI">=`TCH&=EZN#[
M2`LA\`)/\ZY!4NEWW)^/&G6NWH[[R`KVA;74:G9H><D$XJN%E7UC6H(VQK$_
MPPQD*#7EP8ILE77J5DXQ9;]?Q`8_G%_@KR[LKK/8Z*(X.QDBMW=&45>@3S=A
M;>1*WK;@*`N!TIT]`L<S:VMW;87(2R#,WJ23HCAC1:E_+W`;08U]6E:^H3XB
MK&5%W^1^]5?].Y!N4X#+M0XAUFA<6M)MBI6M"A9NOV2(EM2S-A97_A@ZQ=IY
M^BM*BV56;N)%D!03\WMX`[,*F4^T,&.P0WY*VRKRWD2=9&5D989B@]9XU!"5
M`(5N].^N0)?&?=6;(9LA,=<8U8[25^D:LK*98@Q]59&(+T)!9>U>VGE;/I^=
MRU:<U''74!-7WDQ>B9P+J!L3.GNKJR@JTS_F78:]<G3<[.3?UW*8A:,82[('
M:2$MZ-J53S4O`3D\1CK^*X%UE@Z6..@\VC*7$99SY*M&#4!IF#LC;24WM2AJ
M>HRN0L9(#:XLH][D)O*JK!#(%4>:RN10E85**Z[@'V+6HH&9>T/<YG'GG(GV
MW]&.,?:N)FAOY3'VCN;;SZLIQTTU8]QID:VG6R23:<DL\<RQV$EX.QVOJ&Z1
MB$\/;KK?NG:199+#[@6'K6V4@"SD*5VW4(\N0E3U42A0R>FC&IURWVSNY<8]
M]P6_]6YQLY,(+;MUM+ZZ`-V8QD[7]%5%!33?N:/#O2+-R;N%$QZZQ5X<<PN5
M/$+?;C&MH^;/>>,$5QF:(M;AHDM969UZS'TV3@85DVAD'RK"3<RKL&C))T3S
M54=WB/*\?;\<BO<M"T*XK&WUM&25\N\:[-8XE0T<R!F8R%0R!%W.5-`<;E/&
M+^?D,MGBY5F.4R%G<.*-YEHMJ*/*7%4"%0HC#%7+G:@85(T)Z3Y`V3W@>%\M
ML_&*P5"7L%$Y:U5=TYUG/[?"2F5OX]C'LI&&+67ZZ5:@:5!&(JM'N11EIA]*
M.%R$\8"FF^"/!6_VJR\6(R*2Q1S63@""5&68$DAMX]=I&Z!A5$5%!-.IBFDS
M<_W.Q4N5Q[Q2/#>(:S1.IA(`!4(?56->I4T=V<GOT$G&.YCEQ^6>TW*G9_0Z
M/0>/&9UWCG!DK=3K-<A7%JN3:%UG7U5U(R/9)+-(:JDI,>0%!,FW.F]3_5$R
M@#YUELCDAQ>SM+N>>:^O[E[IM[N[!(RT$%*D]6?XAO2:H?1KT#%X_''DMW=6
ML$,-E8VZVJ[415+N%FGK0"H5/(7KVHX].H+:97[+9_:*TU"@HJ/8^D>Z+*:%
MH,1")"LJADD%RTA[%)2RT6R*90:[&1I&TP<X)^0$:S.N']D03![-=SV]O]TK
M8WIVR3<;$43-T_KM9,H6I_4QK'Z=S!>YUY+;PS3_`&VN!9^M'%GS)(%Z_P!%
M;I6)H/TJ-KGP"J3V&IB/;0@;6C>?<:O+LRRF:Z7SSTNQ92^`QCQ-BBHZL5"N
MV.U5M<.[:0@I&P12C4CM`3(.%V"HE,;L(]>4_<.>V:RP%DM/]PM\)"DP_4A+
MNR(X[A@K5VGJ`PJ->E\!AN!=YR\:OP%QF96A/Z7`5%9T\"I84J.A*FFI5.O-
M->BZ'1HT.C1H=&C0Z-&AT:-#HT:'1HT.C1H=&C0Z-&M5]\T<?-?W1OGWS3Y/
M](_PO_3TY/;'?OX=_P"&FO[![=O'M_'6G'?.'WU3_HWU=\X_=G^??YK^KWZ?
M)[*^WX]^W\/YZ8GM'V?#MW_C_+6O_I,Y]0_MQ_\`\3\W3^O/Z_\`[O\`X?;I
MWZ4]OQ_+_I_GI/U/['<?G_U?RU]J?-V_U)^TY_>?-_WP_-_ZW]Y_7Z0>T?;\
M/S_C_+2GL/8\?\#^>M5[\RD?]FOVV/SWYE\Z+]8_U_[C_%[=.3VU_N>/;OV\
M/Y_AIC^PW]OP[]N_C_+\==(/K`?JS]H?D^L/FQ/E_K?YOMU'_P!O]7\N_P#C
M^.I/U_I_GV_Q_#3$^5OD^MP7S?YM]O5Z)Y_\L/7_`(9_0?147ZG\4WI/UOY;
M>?Y/IO3_`/27J/4>1_8^JZ[7C-=M[3X7M%_>I\76II\'7_N]ZU]2FW=UVZY#
MD=-]G7XGO+_:K\+2@K\73_M=J4]:N[;TW:<5>O1?SJPWS?X5]?YE_P#1_P`5
M?Q!](^1_!\CZS^6?H_\`];_CGQ>5ZSUW_M/\.^O]+\/4=8%EO_VB]IYNRD5=
MFVE?,%/.KZ_E]]NWIYNS=^G6W>;/]VLZ^7O_`*E-^ZOL&OE4]7S.V[=U\K?M
M_5I4K;_L_(_[.?L(_P"UO^S_`,X1^L?ZG]#_`!/#UFVO]]?[G_1[7;P_QVUH
MW/\`8;^W_P!?L]_'_'?64O[,-]0_-VW[/[/^C_4W^K_W?_J=(?U^WW/\_:_'
MT_QTO@OL=A_A?Y:S-_GH_4_[YY\W^>_M?I_QO[[_`"]-/L?K[#\O\>C2CV_T
M^/Y_X].LL?\`OY3ZL^?_`/R_]_\`-F_UI_K_`/FO!TDG9?:]GQ_,]OP_G72I
MW;V?:\/R\?Q_EK<-^_2_<?LJ?M?O_P!'[K^K_2Z;^D]_Y:>>X[:T$_F\K]4_
M.7?[OYO^Z)]:_P"L_P!]_4[=//M+[78?G_#\/1J,>RWL]S^7\?Q].OAG^[>?
M4W[A'YG^[_<G^>?X']#^IWZ5^X]OOX_R_'0G8^QV\/YZSPWU1%_5OU<R^IOJ
MCYLG]5__`$[^Y_P^W39?[K>U[1]KVN_ZOQ]/XZ6+^TOL^R/9]GMX?AZ/PUTN
7H]2:'1HT.C1H=&C0Z-&AT:-#HT:__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
